These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1747426)

  • 1. [Immunoenzyme determination of the total level of ceruloplasmin in the serum from patients with hepatocerebral dystrophy].
    Saenko EL; Skorobagat'ko OV; Iaropolov AI
    Biokhimiia; 1991 Sep; 56(9):1640-6. PubMed ID: 1747426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoenzyme determination of total serum ceruloplasmin. Application to Wilson disease.
    Saenko EL; Skorobogatko OV; Yaropolov AI
    Biochem Int; 1991 Mar; 23(5):819-24. PubMed ID: 1883396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of an enzymatic assay for the determination of serum ceruloplasmin.
    Macintyre G; Gutfreund KS; Martin WR; Camicioli R; Cox DW
    J Lab Clin Med; 2004 Dec; 144(6):294-301. PubMed ID: 15614251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the protective effects on the erythrocytes of ceruloplasmin from the blood of healthy donors and patients with hepatocerebral dystrophy].
    Saenko EL; Skorobagat'ko OV; Iaropolov AI
    Biull Eksp Biol Med; 1990 Oct; 110(10):368-70. PubMed ID: 2279084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Factors affecting the concentration of serum ceruloplasmin in Wilson-Konovalov disease].
    Mzhel'skaia TI; Ivanova-Smolenskaia IA; Korobova NV
    Vopr Med Khim; 1994; 40(6):48-53. PubMed ID: 7618303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular forms of ceruloplasmin in hepatolenticular degeneration and their interaction with human erythrocyte ceruloplasmin receptor.
    Puchkova LV; Verbina IA; Denezhkina VV; Vakharlovskii VG; Voitsekhovskii BL; Gaitskhoki VS; Neifakh SA
    Biomed Sci; 1990; 1(5):460-6. PubMed ID: 1966785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma non-ceruloplasmin copper in hepatocerebral dystrophy (criterion for the diagnosis and evaluation of cuprogogue therapy)].
    Botvinnik VS; Lekar' PG; Makarova VA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(3):334-7. PubMed ID: 7257674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Protective effect rendered by human ceruloplasmin on erythrocytes in hepatocerebral dystrophy].
    Saenko EL; Skorobogat'ko OV; Mzhel'skaia TI; Ivanova-Smolenskaia IA; Markova ED; Basevich VV
    Biokhimiia; 1989 Oct; 54(10):1617-22. PubMed ID: 2605268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phenocopy of hepatocerebral dystrophy (Wilson-Konovalov disease)].
    Makarova VA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(11):1606-12. PubMed ID: 7324659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further investigations on ceruloplasmin in hepatolenticular degeneration and on the effect of copper on oxidase activity of ceruloplasmin.
    Wald I; Galewicz A; Górska D
    Pol Med J; 1972; 11(3):733-9. PubMed ID: 5047986
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hepatocerebral dystrophy in the Bashkir ASSR].
    Magzhanov RV; Pertsev GS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(3):346-9. PubMed ID: 6455023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interaction of molecular forms of ceruloplasmin with specific membrane receptors from healthy persons and patients with hepatolenticular degeneration].
    Puchkova LV; Verbina IA; Gaĭtskoki VS; Neĭfakh SA
    Biokhimiia; 1991 Dec; 56(12):2261-9. PubMed ID: 1666959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ceruloplasmin activity in the blood during progressive diseases of the central nervous system].
    Mzhel'skaia TI; Zavalishin IA; Ivanova-Smolenskaia IA; Larskiĭ EG; Basevich VV; Markova ED; Niiazbekova AS
    Lab Delo; 1989; (11):12-6. PubMed ID: 2481091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of apo- and holo-forms of ceruloplasmin in patients with Wilson's disease using native polyacrylamide gel electrophoresis.
    Hirano K; Ogihara T; Ogihara H; Hiroi M; Hasegawa M; Tamai H
    Clin Biochem; 2005 Jan; 38(1):9-12. PubMed ID: 15607310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilson's disease patients with normal ceruloplasmin levels.
    Yüce A; Koçak N; Ozen H; Gürakan F
    Turk J Pediatr; 1999; 41(1):99-102. PubMed ID: 10770682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ceruloplasmin activity and content of the blood of persons with acute and chronic alcoholic intoxication].
    Moshkov KA; Burmistrov SO; Usatenko MS; Grinenko AIa; Petrov VP
    Farmakol Toksikol; 1986; 49(1):92-6. PubMed ID: 3005032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective action of blood ceruloplasmin obtained from normal individuals on red blood cells compared with that from patients with Wilson's disease.
    Saenko EL; Skorobogat'ko OV; Yaropolov AI
    Biomed Sci; 1990; 1(5):453-9. PubMed ID: 1966784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of the blood serum from subjects with hepatolenticular degeneration on the ceruloplasmin activity in the serum of normal and schizophrenic subjects].
    Puzyński S; Kalinowski A
    Neurol Neurochir Psychiatr Pol; 1966 Aug; 16(8):885-90. PubMed ID: 5969522
    [No Abstract]   [Full Text] [Related]  

  • 19. [A commercial immunoenzyme reagent for the determination of ceruloplasmin].
    Kuz'mina NS; Osmanov SK; Nazarenko AA; Lymar' SS; Voloshchuk OM; Iakovleva SA
    Lab Delo; 1991; (4):21-3. PubMed ID: 1715423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Isolation and physico-chemical properties of rat ceruloplasmin].
    Zakharova ET; Vasil'ev VB; Gorbunova VN; Shavlovskiĭ MM
    Biokhimiia; 1983 Oct; 48(10):1709-20. PubMed ID: 6639990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.